184 related articles for article (PubMed ID: 16332457)
1. Selection of a human anti-RhD monoclonal antibody for therapeutic use: impact of IgG glycosylation on activating and inhibitory Fc gamma R functions.
Sibéril S; de Romeuf C; Bihoreau N; Fernandez N; Meterreau JL; Regenman A; Nony E; Gaucher C; Glacet A; Jorieux S; Klein P; Hogarth MP; Fridman WH; Bourel D; Béliard R; Teillaud JL
Clin Immunol; 2006; 118(2-3):170-9. PubMed ID: 16332457
[TBL] [Abstract][Full Text] [Related]
2. A human anti-D monoclonal antibody selected for enhanced FcgammaRIII engagement clears RhD+ autologous red cells in human volunteers as efficiently as polyclonal anti-D antibodies.
Beliard R; Waegemans T; Notelet D; Massad L; Dhainaut F; Romeuf Cd; Guemas E; Haazen W; Bourel D; Teillaud JL; Prost JF
Br J Haematol; 2008 Apr; 141(1):109-19. PubMed ID: 18279459
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of RhD monoclonal antibodies in clinical trials as replacement therapy for prophylactic anti-D immunoglobulin: more questions than answers.
Kumpel BM
Vox Sang; 2007 Aug; 93(2):99-111. PubMed ID: 17683353
[TBL] [Abstract][Full Text] [Related]
4. IgG-Mediated Immune Suppression to Erythrocytes by Polyclonal Antibodies Can Occur in the Absence of Activating or Inhibitory Fcγ Receptors in a Full Mouse Model.
Bernardo L; Yu H; Amash A; Zimring JC; Lazarus AH
J Immunol; 2015 Sep; 195(5):2224-30. PubMed ID: 26188060
[TBL] [Abstract][Full Text] [Related]
5. Galactosylation of human IgG monoclonal anti-D produced by EBV-transformed B-lymphoblastoid cell lines is dependent on culture method and affects Fc receptor-mediated functional activity.
Kumpel BM; Rademacher TW; Rook GA; Williams PJ; Wilson IB
Hum Antibodies Hybridomas; 1994; 5(3-4):143-51. PubMed ID: 7756579
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal anti-D antibodies to prevent alloimmunization: lessons from clinical trials.
Béliard R
Transfus Clin Biol; 2006; 13(1-2):58-64. PubMed ID: 16580863
[TBL] [Abstract][Full Text] [Related]
7. Immunologic basis and immunoprophylaxis of RhD induced hemolytic disease of the newborn (HDN).
Payam Khaja Pasha R; Shokri F
Iran J Immunol; 2008 Dec; 5(4):189-200. PubMed ID: 19098362
[TBL] [Abstract][Full Text] [Related]
8. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.
Stavenhagen JB; Gorlatov S; Tuaillon N; Rankin CT; Li H; Burke S; Huang L; Vijh S; Johnson S; Bonvini E; Koenig S
Cancer Res; 2007 Sep; 67(18):8882-90. PubMed ID: 17875730
[TBL] [Abstract][Full Text] [Related]
9. Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2R gamma(null) mice in vivo.
Ito A; Ishida T; Utsunomiya A; Sato F; Mori F; Yano H; Inagaki A; Suzuki S; Takino H; Ri M; Kusumoto S; Komatsu H; Iida S; Inagaki H; Ueda R
J Immunol; 2009 Oct; 183(7):4782-91. PubMed ID: 19748990
[TBL] [Abstract][Full Text] [Related]
10. [EMABling antibodies: from feto-maternal allo-immunisation prophylaxis to chronic lymphocytic leukaemia therapy].
Urbain R; Teillaud JL; Prost JF
Med Sci (Paris); 2009 Dec; 25(12):1141-4. PubMed ID: 20035694
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and safety of roledumab, a novel human recombinant monoclonal anti-RhD antibody with an optimized Fc for improved engagement of FCγRIII, in healthy volunteers.
Yver A; Homery MC; Fuseau E; Guemas E; Dhainaut F; Quagliaroli D; Beliard R; Prost JF
Vox Sang; 2012 Oct; 103(3):213-22. PubMed ID: 22568808
[TBL] [Abstract][Full Text] [Related]
12. Different types of FCgamma-receptors are involved in anti-Lewis Y antibody induced effector functions in vitro.
Dettke M; Loibner H
Br J Cancer; 2000 Jan; 82(2):441-5. PubMed ID: 10646902
[TBL] [Abstract][Full Text] [Related]
13. Mouse FcgammaRII is a negative regulator of FcgammaRIII in IgG immune complex-triggered inflammation but not in autoantibody-induced hemolysis.
Schiller C; Janssen-Graalfs I; Baumann U; Schwerter-Strumpf K; Izui S; Takai T; Schmidt RE; Gessner JE
Eur J Immunol; 2000 Feb; 30(2):481-90. PubMed ID: 10671203
[TBL] [Abstract][Full Text] [Related]
14. Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcgammaRIIIa.
Iida S; Misaka H; Inoue M; Shibata M; Nakano R; Yamane-Ohnuki N; Wakitani M; Yano K; Shitara K; Satoh M
Clin Cancer Res; 2006 May; 12(9):2879-87. PubMed ID: 16675584
[TBL] [Abstract][Full Text] [Related]
15. Clearance of human IgG1-sensitised red blood cells in vivo in humans relates to the in vitro properties of antibodies from alternative cell lines.
Armour KL; Smith CS; Ip NC; Ellison CJ; Kirton CM; Wilkes AM; Williamson LM; Clark MR
PLoS One; 2014; 9(10):e109463. PubMed ID: 25302805
[TBL] [Abstract][Full Text] [Related]
16. Modulation of tumor growth by inhibitory Fc(gamma) receptor expressed by human melanoma cells.
Cassard L; Cohen-Solal JF; Galinha A; Sastre-Garau X; Mathiot C; Galon J; Dorval T; Bernheim A; Fridman WH; Sautès-Fridman C
J Clin Invest; 2002 Nov; 110(10):1549-57. PubMed ID: 12438452
[TBL] [Abstract][Full Text] [Related]
17. A single recombinant anti-RhD IgG prevents RhD immunization: association of RhD-positive red blood cell clearance rate with polymorphisms in the FcgammaRIIA and FcgammaIIIA genes.
Miescher S; Spycher MO; Amstutz H; De Haas M; Kleijer M; Kalus UJ; Radtke H; Hubsch A; Andresen I; Martin RM; Bichler J
Blood; 2004 Jun; 103(11):4028-35. PubMed ID: 14976055
[TBL] [Abstract][Full Text] [Related]
18. Characterization of a macaque anti-Rh17-like monoclonal antibody.
Blancher A; Roubinet F; Reid ME; Socha WW; Bailly P; Bénard P
Vox Sang; 1998; 75(1):58-62. PubMed ID: 9745155
[TBL] [Abstract][Full Text] [Related]
19. Impact on N-glycosylation profile of monoclonal anti-D antibodies as a way to control their immunoregulatory and cytotoxic properties.
Olovnikova NI; Ershler MA; Grigorieva OV; Petrov AV; Miterev GY
Biochemistry (Mosc); 2012 Aug; 77(8):925-33. PubMed ID: 22860915
[TBL] [Abstract][Full Text] [Related]
20. [Monoclonal antibody against brain derived neurotrophic factor inhibits myeloma growth and angiogenesis in the xenograft NOD/SCID animal model].
Wang YD; Hu Y; Zhang L; Huang J; Sun CY
Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):659-63. PubMed ID: 18399169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
